X

Trial Profile

BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in Patients with Multiple Sclerosis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary)
Indications Neurogenic bladder; Urinary incontinence
Focus Registrational; Therapeutic Use
Sponsors Allergan

Most Recent Events

20 Jul 2018 Results published in the Neurology
10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov .
11 Mar 2014 Planned end date changed from 1 Jun 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com